Kalorama Presents at BIOMedevice San Jose

The point of care diagnostic testing market is over $22 billion, about 2/3rds of that is self-care and physician office based testing.

Point of care testing offers significant benefits in time-to-results, time-to-treatment, diagnostic relevance to providers and even patient confidence.  They tend to cost more than lab-based tests, but in an overall context of care cost, they can prove to contribute to overall savings and outcomes improvement.

Kalorama Information presented at the BioMedevice San Jose – https://biomedevicesanjose.com/ The Presentation will be on “Point of Care: Fast Growth,  New Products, Disruptive Trends. ”

Some key points

  • Point of Care Grows Faster
  • Point of Care Needs to Prove Benefits.
  • As more than a fourth of the IVD market, POC has withstood cost challenges
  •  Cardiac, HbA1c, Tumor Markers, FOB among fast-growing segments

    For a copy of Kalorama Publisher Bruce Carlson’s presentation at the event, please email [email protected]

For More Information on the Point of Care Market, See Kalorama Information’s report:

The Worldwide Market for Point-of-Care (POC) Testing (Infectious Disease Testing, POC Cancer Tests, Rapid Coagulation, Urine Testing, Lipid Tests, Pregnancy Testing, Glucose Testing and Other POC)